

找到约 20,800 条结果 (用时 0.63 秒)

Osimertinib in the treatment of non-small-cell lung cancer: design ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571822/> - 翻译此页

作者 : M Santarpia - 2017 - 被引用次数 : 17 - 相关文章

2017年8月18日 - About 85% of lung cancers are non-small-cell lung cancer (NSCLC), comprising ... benefit from treatment with next-generation ALK inhibitors, including ceritinib, ... The first-generation, reversible EGFR TKIs, gefitinib and erlotinib, are osimertinib resistance, 6 cases acquired C797S resistance mutation in ...

Osimertinib in patients with advanced epidermal growth factor receptor ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455880/> - 翻译此页

作者 : B Ricciuti - 2017 - 被引用次数 : 11 - 相关文章

2017年4月16日 - Currently, lung cancers are classified into non-small cell lung cancers ... However, the predictive significance of these mutations to treatment with EGFR-TKI is still as a potential determinant of resistance to first-generation EGFR-TKIs in vitro, ... Importantly, the acquisition of the T790M mutation leads to an ...

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449484/> - 翻译此页

作者 : TA Barnes - 2017 - 被引用次数 : 22 - 相关文章

2017年5月31日 - Non-small cell lung cancer (NSCLC) accounts for over 80% of lung cancer ... first-line treatment of EGFR-positive lung cancer include first-generation TKIs EGFR mutation-positive advanced NSCLC with acquired resistance to TKI. ... AURA2 is a single-arm, open-label phase II study of osimertinib 80 mg ...

Treatment After First-Generation Epidermal Growth Factor Receptor ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783084/> - 翻译此页

作者 : SN Kazaz - 2017 - 相关文章

Among those inhibitors, third-generation EGFR-TKIs such as osimertinib and rociletinib ... Non-small-cell lung cancer (NSCLC) cases comprise approximately ... significant survival advantages, and it has become a popular treatment ... We aim to review resistance mechanisms against first-/second-generation EGFR-TKIs ...

of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

<https://www.sciencedirect.com/science/article/pii/S1476558617304700> - 翻译此页

作者 : B Oronsky - 2018 - 被引用次数 : 4 - 相关文章

However, a substantial minority (~25%) of patients with non-small cell lung cancer ... for a finite period

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 45389

Manuscript Type: CASE REPORT

Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in squamous cell lung cancer: a case report and review of the literature

Zhang Y *et al.* Osimertinib for T790M-related acquired resistant SCC

Yan Zhang, Hui-Min Chen, Yong-Mei Liu, Feng Peng, Min Yu, Wei-Ya Wang, Heng Xu, Yong-Sheng Wang, You Lu

Abstract

BACKGROUND

Squamous cell lung cancer (SCC) rarely harbors epidermal growth factor receptor

Match Overview

1	Internet 14 words crawled on 03-Dec-2017 www.spandidos-publications.com	1%
2	Internet 14 words crawled on 17-Jul-2018 www.wjgnet.com	1%
3	Internet 12 words crawled on 27-Sep-2018 pesquisa.bvsalud.org	1%

[全部](#)[新闻](#)[图片](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 40,900 条结果 (用时 0.68 秒)

Treatment After First-Generation Epidermal Growth Factor Receptor ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783084/> - 翻译此页

作者: SN Kazaz - 2017 - 相关文章

Among those inhibitors, third-generation EGFR-TKIs such as osimertinib and rociletinib ... Non-small-cell lung cancer (NSCLC) cases comprise approximately ... significant survival advantages, and it has become a popular treatment ... We aim to review resistance mechanisms against first-/second-generation EGFR-TKIs ...

Resistance to epidermal growth factor receptor tyrosine kinase ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001758/> - 翻译此页

作者: GM O'Kane - 2018 - 被引用次数: 1 - 相关文章

2018年6月13日 - Mechanisms of acquired egfr tki resistance can be broadly classified ... NSCLC = non-small-cell lung cancer; EGFR = epidermal growth ... Very recently, the results of the flaura study comparing first-generation egfr tkis with osimertinib In a review of 18 reported cases in 2016, treatment had varied widely.

Mechanisms of acquired resistance to first- and second-generation ...

https://academic.oup.com/annonc/article/29/suppl_1/i10/4860370 - 翻译此页

作者: D Westover - 2018 - 被引用次数: 19 - 相关文章

2018年2月15日 - Abstract. Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour ... growth factor receptor (EGFR) frequently derive significant clinical and radiographic benefits from treatment with EGFR tyrosine kinase inhibitors (TKIs). Fewer than half of the cases of acquired EGFR TKI resistance are ...

Molecular mechanisms of acquired resistance to third-generation ...

https://academic.oup.com/annonc/article/29/suppl_1/i28/4860372 - 翻译此页

作者: C Ricordel - 2018 - 被引用次数: 6 - 相关文章

2018年2月15日 - Lung cancer represents the leading cause of cancer-related deaths worldwide. ... for acquired resistance to first- and second-generation EGFR-TKIs, ... T790M-mutated lung cancer are ... of small-cell lung cancer